Intellia Therapeutics, Inc.

NTLA · Nasdaq · SIC 2835: In Vitro & In Vivo Diagnostic Substances
200
SEC Filings

Business Summary

Overview Intellia Therapeutics, Inc. (we, us, our, Intellia, or the Company) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of di...

Next Earnings

Q2 FY2026 — expected 2026-09-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNTLAdiscussed_in_filing Cybersecurity
topic_mentionNTLAdiscussed_in_filing Cybersecurity
topic_mentionNTLAdiscussed_in_filing Healthcare & Bio
topic_mentionNTLAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-076550EDGAR95K words
2025-02-272024-12-310000950170-25-029007EDGAR—
2024-02-222023-12-310000950170-24-018736EDGAR—
2023-02-232022-12-310000950170-23-004097EDGAR—
2022-02-242021-12-310000950170-22-001981EDGAR—
2021-02-262020-12-310001564590-21-009011EDGAR—
2020-02-272019-12-310001564590-20-007409EDGAR—
2019-02-272018-12-310001564590-19-004680EDGAR—
2018-03-142017-12-310001564590-18-005544EDGAR—
2017-03-142016-12-310001193125-17-082186EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269680EDGAR62K words
2025-08-072025-06-300000950170-25-104987EDGAR—
2025-05-082025-03-310000950170-25-066914EDGAR—
2024-11-072024-09-300000950170-24-123276EDGAR—
2024-08-082024-06-300000950170-24-093907EDGAR—
2024-05-092024-03-310000950170-24-057046EDGAR—
2023-11-092023-09-300000950170-23-062011EDGAR—
2023-08-032023-06-300000950170-23-037996EDGAR—
2023-05-042023-03-310000950170-23-017866EDGAR—
2022-11-032022-09-300000950170-22-021835EDGAR—
2022-08-042022-06-300000950170-22-014731EDGAR—
2022-05-052022-03-310000950170-22-007805EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-020001193125-26-084309EDGAR2K words
2026-02-260001193125-26-073456EDGAR—
2026-01-270001193125-26-023387EDGAR—
2026-01-090001193125-26-008307EDGAR—
2025-11-100001193125-25-274596EDGAR—
2025-11-060001193125-25-269479EDGAR—
2025-10-290001193125-25-256378EDGAR—
2025-10-270001193125-25-250757EDGAR—
2025-09-250001193125-25-217484EDGAR—
2025-08-070000950170-25-104574EDGAR—

200 total filings indexed. 168 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ACHV — ACHIEVE LIFE SCIENCES, INC. TKNO — Alpha Teknova, Inc. AWHL — Aspira Women's Health Inc. BMRA — BIOMERICA INC BZYR — BURZYNSKI RESEARCH INSTITUTE INC CDIO — Cardio Diagnostics Holdings, Inc. CLDX — Celldex Therapeutics, Inc. IDXX — IDEXX LABORATORIES INC /DE

Company Identity

CIK0001652130
TickerNTLA
ExchangeNasdaq
SIC2835: In Vitro & In Vivo Diagnostic Substances
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 2b29d4c342cb30647ac41c7a42928d55249d157bd8a5a705c02acedd7e527ff4
parent: 63d0e749c8f973aeaebdaf91d2b84d89ef9f5d45e0d436505faff1ebf8b67bde
content hash: 61af657c9effbda418338c28bc76c56cd0d17241df1ebdf4298d067f67578c20
signed: 2026-04-13T04:46:36.170Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf